Arrowstreet Capital Limited Partnership Takes $9.66 Million Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Arrowstreet Capital Limited Partnership purchased a new stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,075,911 shares of the biotechnology company's stock, valued at approximately $9,662,000. Arrowstreet Capital Limited Partnership owned approximately 0.75% of Aurinia Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. SBI Securities Co. Ltd. purchased a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter valued at approximately $25,000. Blue Trust Inc. boosted its position in shares of Aurinia Pharmaceuticals by 3,041.4% in the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock worth $57,000 after buying an additional 6,174 shares during the period. FMR LLC grew its holdings in shares of Aurinia Pharmaceuticals by 44.8% during the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company's stock valued at $93,000 after buying an additional 3,919 shares in the last quarter. Virtu Financial LLC acquired a new position in Aurinia Pharmaceuticals during the fourth quarter valued at $96,000. Finally, Union Bancaire Privee UBP SA purchased a new stake in Aurinia Pharmaceuticals in the 4th quarter worth about $108,000. Institutional investors own 36.83% of the company's stock.

Analysts Set New Price Targets

Separately, StockNews.com raised Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, March 27th.

Remove Ads

Insider Transactions at Aurinia Pharmaceuticals

In related news, insider Greg Keenan sold 8,305 shares of the business's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $8.23, for a total value of $68,350.15. Following the completion of the sale, the insider now owns 153,484 shares of the company's stock, valued at approximately $1,263,173.32. The trade was a 5.13 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Peter Greenleaf sold 195,593 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $1,564,744.00. Following the completion of the transaction, the chief executive officer now owns 1,953,892 shares in the company, valued at $15,631,136. This represents a 9.10 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 343,898 shares of company stock valued at $2,753,094. 4.30% of the stock is owned by insiders.

Aurinia Pharmaceuticals Stock Up 1.0 %

AUPH stock traded up $0.07 during midday trading on Friday, reaching $7.41. The company had a trading volume of 1,384,955 shares, compared to its average volume of 1,358,968. The company has a 50 day moving average of $8.01 and a two-hundred day moving average of $8.09. The company has a market capitalization of $1.02 billion, a P/E ratio of -49.40 and a beta of 1.20. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.71 and a 1 year high of $10.67. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.